Antacids Market Report 2025

The antacids market size has grown steadily in recent years. It will grow from $9.54 billion in 2024 to $9.9 billion in 2025 at a compound annual growth rate (CAGR) of 3.8%. The growth in the historic period can be attributed to historical pricing and accessibility, historical dietary shifts, economic conditions and lifestyle changes, medical advancements and awareness, historical population demographics.

The antacids market size is expected to see steady growth in the next few years. It will grow to $11.24 billion in 2029 at a compound annual growth rate (CAGR) of 3.2%. The growth in the forecast period can be attributed to market competition and industry trends, consumer preferences and brand loyalty, environmental factors and lifestyle changes, emerging health conditions, economic conditions and healthcare spending. Major trends in the forecast period include health consciousness and awareness, technological advancement, consumer preferences for natural remedies, regulatory changes and compliance, rising incidence of digestive disorders.

The growth of the antacids market is significantly influenced by poor lifestyle choices, leading to a higher prevalence of acidity. Unhealthy lifestyle practices, such as sedentary jobs, inadequate sleep quality, and irregular dietary habits, contribute to elevated stomach acidity levels, resulting in conditions such as gastroesophageal reflux disease (GERD). The American College of Gastroenterology reports that approximately 60 million Americans suffer from GERD, fueling the demand for antacids.

The anticipated increase in the prevalence of inflammatory bowel disease is expected to drive the growth of the animal growth promoters and performance enhancers market. Inflammatory bowel disease (IBD) encompasses a group of conditions characterized by chronic inflammation in the digestive tract. Antacids, designed to regulate stomach acid levels, are commonly used for managing heartburn and indigestion. According to the International Foundation for Gastrointestinal Disorders (IFFGD), it is projected that 5-10% of the global population will have irritable bowel syndrome (IBS) by 2023, affecting between 25 and 45 million people in the United States. Additionally, a survey by the American Gastroenterological Association covering 33 countries on 6 continents revealed that more than 40% of adult respondents worldwide have functional gastrointestinal disorders (FGID), impacting their quality of life and healthcare utilization. Consequently, the increasing prevalence of inflammatory bowel disease is expected to propel the growth of the animal growth promoters and performance enhancers market in the future.

An emerging trend in the antacid market is the development of mouth-melting antacids. Traditionally available in tablet, liquid, and powder forms, mouth-melting antacids utilize micro-mouth melting granules that easily dissolve in the mouth. Sunpharma's 'Pepmelt' is an example of a mouth-melting instant relief antacid that combines herbal constituents with contemporary mouth-melting technology.

Major companies in the antacids market are diversifying their product offerings by introducing multiple antacid flavors to enhance market profitability. Antacid flavors refer to the various tastes available for antacid products. Wonderbelly, a US-based digestive medicine company, introduced three antacid flavors, namely Fruity Cereal (exclusive to Target stores), Strawberry Milkshake, and Watermelon Mint, in March 2023. Wonderbelly's Antacid, containing calcium carbonate as its active ingredient, distinguishes itself as a non-GMO and vegan product without talc, dyes, gluten, dairy, common allergens, synthetic sweeteners, artificial flavors, parabens, and preservatives. Developed in collaboration with gastroenterologists and pharmaceutical manufacturers, these products prioritize quality.

Leading companies in the antacids market are developing innovative products, such as anti-reflux antacids, to meet the increasing consumer demand for effective solutions for heartburn and acid reflux. Anti-reflux antacids are medications specially formulated to ease symptoms of gastroesophageal reflux disease (GERD) and related conditions by neutralizing stomach acid. For example, in June 2024, Akums Drugs and Pharmaceuticals, an India-based pharmaceutical manufacturing company, introduced a new chewable tablet for heartburn relief that combines sodium alginate and potassium bicarbonate. Approved by the Drugs Controller General of India (DCGI), this dual-action formulation is designed to relieve GERD symptoms effectively. Sodium alginate creates a protective gel barrier to prevent acid reflux, while potassium bicarbonate neutralizes stomach acid for immediate relief.

Major companies operating in the antacids market include Walmart Equate LLC, Private Label, Pfizer Inc, Bayer AG, Sanofi S.A., Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim GmbH, Reckitt Benckiser Group plc, WellSpring Pharmaceutical Corporation, Xiuzheng Pharmaceutical Group Company Limited, Bausch Health Companies Inc., Sun Pharmaceuticals Industries Ltd., Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals plc, Alkem Laboratories Ltd., Conba Group Co. Ltd., Chattem Chemicals Inc., China Resources Sanjiu Medical & Pharmaceutical Co. Ltd., Thornton and Ross Ltd., McNeil Consumer Pharmaceuticals Co., Advance Pharmaceutical Inc.

North America was the largest region in the antacids market in 2024. The Middle East is expected to be the fastest-growing region in the global antacids market share. The regions covered in the antacids market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the antacids market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Antacid drugs are medications used to neutralize stomach acid, providing relief from conditions such as acid reflux, heartburn, and indigestion. They counteract the stomach's acid, easing symptoms, and are available without a prescription in liquid or chewable tablet form. The drug classes within antacids include proton pump inhibitors, H2 antagonists, surgical simulators, and acid neutralizers, available in tablets, liquid, or powder forms.

The primary classes of antacids are proton pump inhibitors, H2 antagonists, acid neutralizers, and pro-motility agents. Proton pump inhibitors significantly and for an extended period reduce stomach acid production by irreversibly blocking the H+/K+ ATPase proton pump in the stomach. Antacids come in various formulations, including tablets, liquids, powders, and others, and are distributed through channels such as hospital pharmacies, retail pharmacies, and other outlets.

The antacids market research report is one of a series of new reports that provides antacids market statistics, including antacids industry global market size, regional shares, competitors with an antacids market share, detailed antacids market segments, market trends, and opportunities, and any further data you may need to thrive in the antacids industry. This antacids market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The antacids market consists of sales of Alka Seltzer, Maalox, Mylanta, Rolaids, Tums, and Pepto-Bismol. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.